贵州三力：拟变更公司证券简称为"三力制药"。 ...

格隆汇11月27日｜贵州三力(603439.SH)公告称，公司于2025年11月27日召开董事会，审议通过将证券 简称由"贵州三力"变更为"三力制药"，公司全称和证券代码保持不变。本次变更证券简称旨在使证券简 称更清晰反映公司主营业务，强化企业品牌形象。变更后的证券简称与公司主营业务和战略规划相匹 配，符合相关法律法规。该事项尚需向上海证券交易所申请，并经上海证券交易所办理后方可实施。 ...

Group 1 - The core viewpoint of the news is that Guizhou Sanli's stock has experienced fluctuations, with a recent decline of 2.02% and a total market value of 5.169 billion yuan [1] - As of November 17, Guizhou Sanli's stock price is 12.64 yuan per share, with a trading volume of 56.89 million yuan and a turnover rate of 1.11% [1] - The company has seen a net outflow of main funds amounting to 4.71 million yuan, with significant selling pressure observed [1] Group 2 - For the year-to-date, Guizhou Sanli's stock price has decreased by 0.19%, while it has increased by 2.85% over the last five trading days [1] - The company's revenue composition includes 60.03% from respiratory medications, 13.75% from tonics, and 9.77% from gynecological medications [1] - As of September 30, the number of shareholders has increased to 26,300, with a decrease in average circulating shares per person by 1.96% [2] Group 3 - For the period from January to September 2025, Guizhou Sanli reported a revenue of 1.038 billion yuan, reflecting a year-on-year decrease of 28.24% [2] - The net profit attributable to the parent company for the same period was 80.787 million yuan, down 58.39% year-on-year [2] - Since its A-share listing, Guizhou Sanli has distributed a total of 362 million yuan in dividends, with 260 million yuan distributed over the past three years [3]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Views - The company reported a significant decline in performance, with a 28.24% year-on-year decrease in revenue for the first nine months of 2025, totaling 1.038 billion yuan. The net profit attributable to the parent company fell by 58.39% to 81 million yuan, and the net profit after deducting non-recurring items decreased by 64.49% to 66 million yuan [2][6]. - In Q3 2025, the company achieved revenue of 337 million yuan, down 36.10% year-on-year, with a net profit of -2 million yuan and a net profit after deducting non-recurring items of -5 million yuan [2][6]. - The company is actively expanding its OTC channel network, which has led to a significant increase in operational costs, while the scale effect of the channel has not yet been fully realized [12]. Financial Performance Summary - For Q3 2025, the gross profit margin was 71.03%, a slight increase of 0.19 percentage points year-on-year, while the net profit margin attributable to the parent company was -0.68%, a decrease of 15.30 percentage points year-on-year [12]. - Sales expenses for Q3 2025 amounted to 201 million yuan, a decrease of 6.79% year-on-year, with a sales expense ratio of 59.75%, an increase of 18.79 percentage points year-on-year [12]. - The company expects net profits attributable to the parent company for 2025-2027 to be 137 million yuan, 146 million yuan, and 158 million yuan, respectively, with corresponding EPS of 0.34 yuan, 0.36 yuan, and 0.39 yuan [12].

Core Points - The Shanghai Composite Index is at 4019.98 points, slightly down by 0.24%, with a total trading volume of 157.39 billion yuan [1] - A total of 58 A-shares have surpassed their annual line, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The top three stocks with the highest deviation rates from the annual line are: - Dae Oriental (600327) with a deviation rate of 9.69% and a daily increase of 10.06% [1] - Huaying Technology (000536) with a deviation rate of 6.49% and a daily increase of 9.94% [1] - *ST Jinke (000656) with a deviation rate of 4.38% and a daily increase of 4.76% [1] Trading Activity - The trading turnover rate for Dae Oriental is 15.27%, while Huaying Technology has a turnover rate of 4.22% [1] - The overall trading volume for A-shares today is reported at 157.39 billion yuan [1] Additional Stocks - Other stocks that have recently crossed the annual line include: - Huicheng Environmental Protection (300779) with a deviation rate of 3.10% [1] - Guizhou Sanli (603439) with a deviation rate of 2.82% [1] - Yiduoli (300381) with a deviation rate of 2.61% [1]

Core Viewpoint - Guizhou Sanli Pharmaceutical Co., Ltd. has signed a concerted action agreement between its controlling shareholder Zhang Hai and Hainan Yuexin Pharmaceutical Investment Partnership, which collectively holds 48.68% of the company's shares, enhancing their influence over corporate decisions [2][11]. Group 1: Shareholder Information - After the signing of the concerted action agreement, the controlling shareholder and its concerted action parties hold a total of 199,056,487 shares, accounting for 48.68% of the total share capital [3][11]. - The agreement does not involve any changes in the individual shareholdings of the shareholders, but rather increases the combined shareholding percentage due to the signing of the agreement [2][11]. Group 2: Agreement Details - The parties involved in the agreement are Zhang Hai, the largest shareholder and actual controller of Guizhou Sanli, and Hainan Yuexin Pharmaceutical Investment Partnership, which holds 20,190,100 shares, representing 4.9373% of the total share capital [4]. - The agreement stipulates that both parties will communicate and reach consensus on proposals before submitting them to the board or shareholders' meeting [5][6]. Group 3: Duration and Commitments - The concerted action agreement is effective for 12 months from the date of signing, with the possibility of extension upon mutual agreement [7]. - Both parties commit to maintaining their rights and obligations under the agreement, regardless of any changes in their shareholding proportions during the agreement period [8][9].

Core Points - Guizhou Sanli Pharmaceutical Co., Ltd. announced the signing of a "Joint Action Agreement" between controlling shareholder Zhang Hai and Hainan Yuexin Pharmaceutical Investment Partnership, which holds 4.94% of the company's shares [2] - Following the agreement, the combined shareholding of both parties amounts to 187,858,540 shares, representing 45.94% of the total share capital of the company [2] - Due to the familial relationship between shareholder Wang Huiying and Zhang Hai, they are considered to have a unified action relationship, resulting in a total shareholding of 199,056,487 shares, or 48.68% of the total share capital [2]

Core Viewpoint - Guizhou Sanli (603439.SH) has signed a concerted action agreement between its controlling shareholder Zhang Hai and Hainan Yuexin Pharmaceutical Investment Partnership, which holds 4.94% of the company's shares, resulting in a combined ownership of 45.94% of the total share capital [1] Summary by Relevant Sections - **Shareholding Structure** - After the signing of the concerted action agreement, the total shares held by the controlling shareholder and its concerted parties amount to 199,056,487 shares, representing 48.68% of the total share capital [1] - **Controlling Shareholder** - The controlling shareholder and actual controller of the company remains Zhang Hai, with no changes following the agreement [1]

股票上市地点：上海证券交易所 股票简称：贵州三力 贵州三力制药股份有限公司 详式权益变动报告书 上市公司名称：贵州三力制药股份有限公司 股票代码：603439 信息披露义务人一：张海 注册地址：贵州省贵阳市南明区**** 通讯地址：贵州省贵阳市南明区**** 信息披露义务人二：海南悦欣医药投资合伙企业（普通合伙） 注册地址：海南省洋浦经济开发区*** 通讯地址：海南省洋浦经济开发区*** 信息披露义务人一之一致行动人：王惠英 注册地址：贵州省贵阳市南明区**** 通讯地址：贵州省贵阳市南明区**** 股份变动性质：信息披露义务人签署一致行动协议，不涉及持股数量的增减 签署日期：二零二五年十一月七日 2 | | | | 第一节 释义 . | | --- | | 第二节 信息披露义务人介绍 5 | | 第三节 权益变动目的及持股计划 . | | 第四节 权益变动方式 | | 第五节 资金来源 . | | 第六节 后续计划 . | | 第七节 对上市公司的影响分析 . | | 第八节 与上市公司之间的重大交易 | | 第九节 前六个月内买卖上市公司股份的情况 - | | 第十节 信息披露义务人的财务资料 . | | ...

证券代码：603439 证券简称：贵州三力 公告编号：2025-060 贵州三力制药股份有限公司 关于控股股东签署一致行动协议暨权益变动 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 贵州三力制药股份有限公司（以下简称"公司"）于近日收到控股股东张 海先生与持公司股份 4.94%的股东海南悦欣医药投资合伙企业（普通合伙，以下 简称"悦欣医药"）共同签署的《一致行动协议》，期限自协议签署之日起 12 个 月。本次股东签署《一致行动协议》后，双方合计持有公司股份 187,858,540 股， 占公司总股本的 45.94%。 因公司股东王惠英系控股股东张海的母亲，两人存在一致行动关系。上 述《一致行动协议》签署后，公司控股股东及其一致行动人合计持有公司股份 199,056,487 股，占公司总股本的 48.68%。 本次权益变动不涉及股东方各自持股数量的增减，系控股股东张海与股 东悦欣医药签署《一致行动协议》导致其合计持有公司股份及比例的增加，不触 及要约收购。 本次签署《一致行动协议》，公司的控股股 ...